Sight Sciences, Inc. (SGHT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Sight Sciences, Inc. is an ophthalmic medical device company operating in two segments: Surgical Glaucoma (OMNI and SION products) and Dry Eye (TearCare System). The company is classified as an emerging growth company and a smaller reporting company. As of June 30, 2025, the company had 52,033,403 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $19.6 million | $21.4 million | $37.1 million | $40.6 million |
| Gross Profit | $16.6 million | $18.3 million | $31.7 million | $34.8 million |
| Gross Margin | 84.8% | 85.8% | 85.5% | 85.7% |
| Net Loss | $(11.9) million | $(12.3) million | $(26.1) million | $(28.6) million |
| Diluted EPS | $(0.23) | $(0.25) | $(0.51) | $(0.58) |
| Cash & Equivalents | $101.5 million (as of June 30, 2025) | |||
| Long-Term Debt | $39.8 million (net of discounts) | |||
| Operating Cash Flow | N/A | $(19.1) million | $(19.3) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 8.5% in Q2 and 8.8% YTD compared to the prior year.
- Surgical Glaucoma: Revenue declined 5.0% (Q2) and 5.6% (YTD) due to reduced unit utilization per facility, driven by Medicare Administrative Contractor (MAC) restrictions on combining MIGS procedures with cataract surgery.
- Dry Eye: Revenue plummeted 70.4% (Q2) and 65.9% (YTD) following a price increase for TearCare products in October 2024, which reduced customer demand as the company shifts strategy toward reimbursed market access rather than cash-pay sales.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 10.5% in Q2 and 9.1% YTD, primarily due to lower legal expenses and stock-based compensation.
- Margin Pressure: Gross margins compressed slightly due to higher overhead costs per unit and tariff-related expenses ($0.1 million incurred YTD) on products manufactured in China.
- Debt Milestones: The company failed to meet performance milestones required to extend its interest-only period on the Hercules Loan Agreement or access Tranche 2 funding ($10 million).
Outlook, Risks, and Contingencies
- Liquidity: Management believes current cash ($101.5 million) and existing liquidity sources are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring net losses.
- Debt Covenants: The company remains in compliance with covenants under the Hercules Loan Agreement. The interest-only period is no longer extendable, and principal repayments will begin in 2026.
- Legal Proceedings: A significant patent infringement lawsuit against Alcon and Ivantis regarding the Hydrus Microstent resulted in a $34 million jury verdict in April 2024. However, the judgment has not been entered, and Alcon has filed for ex parte reexaminations of the patents. The outcome remains uncertain and could materially impact future royalties.
- Geopolitical Risks: Tariffs on products imported from China are expected to negatively impact gross margins. The company is evaluating alternative manufacturing locations outside of China, with some capacity expected in Q1 2026.
- Reimbursement Strategy: The company is actively pursuing reimbursement coverage for Dry Eye products, which currently lack meaningful Medicare or private payor coverage.
Investor Verification Checklist
- Medicare Restrictions: Verify the extent of revenue impact from MAC Local Coverage Determinations (LCDs) restricting MIGS procedures combined with cataract surgery.
- Patent Litigation Status: Monitor the status of the Alcon/Ivantis lawsuit, specifically the outcome of the ex parte reexaminations filed in June 2025 and the entry of the final judgment.
- Tariff Exposure: Assess the company's progress in qualifying non-China manufacturing facilities to mitigate tariff costs on OMNI, SION, and TearCare products.
- Dry Eye Strategy: Evaluate the timeline and success of the shift from cash-pay to reimbursed market access for the TearCare system following the price increase.
- Debt Service: Confirm the company's ability to meet principal repayment obligations starting in 2026 given the current burn rate and revenue trends.